Repression of BCL2 by the tumor suppressor activity of the lysyl oxidase propeptide inhibits transformed phenotype of lung and pancreatic cancer cells - PubMed (original) (raw)
Repression of BCL2 by the tumor suppressor activity of the lysyl oxidase propeptide inhibits transformed phenotype of lung and pancreatic cancer cells
Min Wu et al. Cancer Res. 2007.
Abstract
The gene encoding lysyl oxidase (LOX) was identified as the ras recision gene (rrg), with the ability to revert Ras-mediated transformation of NIH 3T3 fibroblasts. Mutations in RAS genes have been found in approximately 25% of lung cancers and in 85% of pancreatic cancers. In microarray analysis, these cancers were found to display reduced LOX gene expression. Thus, the ability of the LOX gene to repress the transformed phenotype of these cancer cells was tested. LOX is synthesized as a 50-kDa secreted precursor Pro-LOX that is processed to the 32-kDa active enzyme (LOX) and to an 18-kDa propeptide (LOX-PP). Recently, we mapped the rrg activity of Pro-LOX to the LOX-PP in Ras-transformed NIH 3T3 cells. Ectopic Pro-LOX and LOX-PP expression in H1299 lung cancer cells inhibited growth in soft agar and invasive colony formation in Matrigel and reduced activation of extracellular signal-regulated kinase (ERK) and Akt, with LOX-PP showing substantially higher activity. Similarly, LOX-PP expression in PANC-1 pancreatic cancer cells effectively reduced ERK and Akt activity and inhibited growth in soft agar and ability of these cells to migrate. Nuclear Factor-kappaB (NF-kappaB) and its target gene BCL2, which are overexpressed in 70% to 75% of pancreatic cancers, have recently been implicated in invasive phenotype. LOX-PP substantially reduced NF-kappaB and Bcl-2 levels. Reintroduction of Bcl-2 into PANC-1 or H1299 cells expressing LOX-PP restored the transformed phenotype, suggesting that Bcl-2 is an essential target. Thus, LOX-PP potently inhibits invasive phenotype of lung and pancreatic cancer cells, suggesting potential therapeutic applications in treatment of these cancers.
Similar articles
- The tumor suppressor activity of the lysyl oxidase propeptide reverses the invasive phenotype of Her-2/neu-driven breast cancer.
Min C, Kirsch KH, Zhao Y, Jeay S, Palamakumbura AH, Trackman PC, Sonenshein GE. Min C, et al. Cancer Res. 2007 Feb 1;67(3):1105-12. doi: 10.1158/0008-5472.CAN-06-3867. Cancer Res. 2007. PMID: 17283144 - EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation.
Jiang K, Delarue FL, Sebti SM. Jiang K, et al. Oncogene. 2004 Feb 5;23(5):1136-45. doi: 10.1038/sj.onc.1207236. Oncogene. 2004. PMID: 14647415 - The propeptide domain of lysyl oxidase induces phenotypic reversion of ras-transformed cells.
Palamakumbura AH, Jeay S, Guo Y, Pischon N, Sommer P, Sonenshein GE, Trackman PC. Palamakumbura AH, et al. J Biol Chem. 2004 Sep 24;279(39):40593-600. doi: 10.1074/jbc.M406639200. Epub 2004 Jul 23. J Biol Chem. 2004. PMID: 15277520 - Paradoxical roles for lysyl oxidases in cancer--a prospect.
Payne SL, Hendrix MJ, Kirschmann DA. Payne SL, et al. J Cell Biochem. 2007 Aug 15;101(6):1338-54. doi: 10.1002/jcb.21371. J Cell Biochem. 2007. PMID: 17471532 Review. - Lysyl oxidase-like protein localizes to sites of de novo fibrinogenesis in fibrosis and in the early stromal reaction of ductal breast carcinomas.
Decitre M, Gleyzal C, Raccurt M, Peyrol S, Aubert-Foucher E, Csiszar K, Sommer P. Decitre M, et al. Lab Invest. 1998 Feb;78(2):143-51. Lab Invest. 1998. PMID: 9484712 Review.
Cited by
- Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis?
Martinez-Useros J, Garcia-Foncillas J. Martinez-Useros J, et al. Biomed Res Int. 2016;2016:4873089. doi: 10.1155/2016/4873089. Epub 2016 Sep 1. Biomed Res Int. 2016. PMID: 27689078 Free PMC article. Review. - Transcriptome analysis of PPARγ target genes reveals the involvement of lysyl oxidase in human placental cytotrophoblast invasion.
Segond N, Degrelle SA, Berndt S, Clouqueur E, Rouault C, Saubamea B, Dessen P, Fong KS, Csiszar K, Badet J, Evain-Brion D, Fournier T. Segond N, et al. PLoS One. 2013 Nov 12;8(11):e79413. doi: 10.1371/journal.pone.0079413. eCollection 2013. PLoS One. 2013. PMID: 24265769 Free PMC article. - A polymorphism in the lysyl oxidase propeptide domain accelerates carcinogen-induced cancer.
de la Cueva A, Emmerling M, Lim SL, Yang S, Trackman PC, Sonenshein GE, Kirsch KH. de la Cueva A, et al. Carcinogenesis. 2018 Jul 3;39(7):921-930. doi: 10.1093/carcin/bgy045. Carcinogenesis. 2018. PMID: 29579155 Free PMC article. - Targeting Lysyl Oxidase Family Meditated Matrix Cross-Linking as an Anti-Stromal Therapy in Solid Tumours.
Setargew YFI, Wyllie K, Grant RD, Chitty JL, Cox TR. Setargew YFI, et al. Cancers (Basel). 2021 Jan 27;13(3):491. doi: 10.3390/cancers13030491. Cancers (Basel). 2021. PMID: 33513979 Free PMC article. Review. - Collagen Biosynthesis, Processing, and Maturation in Lung Ageing.
Onursal C, Dick E, Angelidis I, Schiller HB, Staab-Weijnitz CA. Onursal C, et al. Front Med (Lausanne). 2021 May 20;8:593874. doi: 10.3389/fmed.2021.593874. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34095157 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous